Soleo Health announced that it joined the treatment center directory for Givlaari and can now administer it for adults with AHP. Givlaari, managed by Alnylam Pharmaceuticals (NSDQ:ALNY), is the first FDA-approved treatment for acute hepatic porphyria (AHP) in adults. The once-monthly injection for subcutaneous use reduces the levels of neurotoxins associated with AHP attacks and […]
Alnylam Pharmaceuticals
Biotech, pharma chime in over Trump’s move to halt immigration program
On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in the U.S. as children. Attorney general Jeff Sessions said Tuesday morning that Trump would move to halt the Deferred Action for Childhood Arrivals program in six months, unless […]
Alnylam, The Medicines Co., detail Phase III trial for RNA-based heart drug
The Medicines Co. (NSDQ:MDCO) and Alnylam Pharmaceuticals (NSDQ:ALNY) said today that they’ve reached a deal with the FDA over a Phase III trial for the companies’ RNA-based cholesterol-lowering drug, inclisiran. If approved, it would be the 1st RNA-interference therapy on the market. The drug is a part of a new group of drugs called PCSK9 […]
Acuitas touts lipid-nanoparticle delivery of mRNA vaccine for Zika
Acuitas Therapeutics touted preliminary data that evaluated its messenger RNA vaccine for the Zika virus. The company uses a lipid-nanoparticle delivery system to introduce its mRNA vaccine into cells. The team’s work, which was published in Nature, showed that a single low-dose immunization with its vaccine triggered an immune response in animals and protected them from infection at […]
Codiak BioSciences lures Alnylam vet Sorensen to lead clinical program
Codiak BioSciences said today that it has named former Alnylam Pharmaceuticals (NSDQ:ALNY) executive Dr. Benny Sorensen as vice president and head of clinical development. Sorensen was Alnylam’s senior director of clinical research, leading the preclinical, clinical, regulatory and commercial strategies for hematology products. He also worked for Baxter (NYSE:BAX), advancing hematology therapies through Phase III pivotal development. Woburn, Mass.-based […]
